Cellusion Entered into an Exclusive License Agreement with Celregen for CLS001 in the Greater China
Shots:
- Cellusion to receive ~$100M in upfront, development & sales milestones along with royalties. The companies will use their strengths to provide novel regenerative therapy to eligible patients in Greater China
- Celregen to get an exclusive right to develop, manufacture & commercialize CLS001 for bullous keratopathy in the Greater China region incl. Mainland China, Hong Kong, Macau & Taiwan while Cellusion holds the rights for CLS001 in other regions
- The patient recruitment will initiate in 2022 for the investigator-initiated study of CLS001 at the Keio University Hospital while the study is expected to be initiated in Japan within a few years, based on the global studies in the US & EU region
Ref: Businesswire | Image: Cellusion
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
